Advanced search
1 file | 1.26 MB Add to list

Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease : a practical overview

(2017) DRUGS. 77(4). p.363-377
Author
Organization
Abstract
The introduction of biologic therapy has revolutionized the treatment of inflammatory bowel disease (IBD). However, like all therapeutic proteins, monoclonal antibodies have immunogenic potential which is influenced by multiple drug- and patient-related factors. The reported incidence of anti-drug antibodies (ADAs) towards biologic drugs in IBD varies greatly in the literature and depends not only on differences in sensitization but also on the assaymethodology and the timepoint of measurement. Sensitization with formation of ADAsis associated with an increased risk of infusion reactions, accelerated drug clearance, and a loss of response (LOR) to drug. Recently, a greater understanding of the pharmacokinetics of therapeutic antibodies has led to the development of new strategies to reduce immunogenicity and more efficient use of these drugs. These preventive strategies include regular scheduled dosing with maintenance of stable therapeutic trough drug concentrations, and co-administration of an immunosuppressive. Sub-therapeutic drug concentrations with escalation, whereas the presence of high concentrations of ADAs requires a switch to another therapeutic agent.
Keywords
PLACEBO-CONTROLLED TRIAL, INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY, CROHNS-DISEASE, MAINTENANCE THERAPY, RHEUMATOID-ARTHRITIS, CERTOLIZUMAB PEGOL, DOUBLE-BLIND, INFLIXIMAB ANTIBODIES, ULCERATIVE-COLITIS, EPISODIC TREATMENT

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.26 MB

Citation

Please use this url to cite or link to this publication:

MLA
Hindryckx, Pieter et al. “Incidence, Prevention and Management of Anti-drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease : a Practical Overview.” DRUGS 77.4 (2017): 363–377. Print.
APA
Hindryckx, P., Novak, G., Vande Casteele, N., Khanna, R., Laukens, D., Vipul, J., & Feagan, B. G. (2017). Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease : a practical overview. DRUGS, 77(4), 363–377.
Chicago author-date
Hindryckx, Pieter, Gregor Novak, Niels Vande Casteele, Reena Khanna, Debby Laukens, Jairath Vipul, and Brian G Feagan. 2017. “Incidence, Prevention and Management of Anti-drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease : a Practical Overview.” Drugs 77 (4): 363–377.
Chicago author-date (all authors)
Hindryckx, Pieter, Gregor Novak, Niels Vande Casteele, Reena Khanna, Debby Laukens, Jairath Vipul, and Brian G Feagan. 2017. “Incidence, Prevention and Management of Anti-drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease : a Practical Overview.” Drugs 77 (4): 363–377.
Vancouver
1.
Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Vipul J, et al. Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease : a practical overview. DRUGS. 2017;77(4):363–77.
IEEE
[1]
P. Hindryckx et al., “Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease : a practical overview,” DRUGS, vol. 77, no. 4, pp. 363–377, 2017.
@article{8518635,
  abstract     = {The introduction of biologic therapy has revolutionized the treatment of inflammatory bowel disease (IBD). However, like all therapeutic proteins, monoclonal antibodies have immunogenic potential which is influenced by multiple drug- and patient-related factors. The reported incidence of anti-drug antibodies (ADAs) towards biologic drugs in IBD varies greatly in the literature and depends not only on differences in sensitization but also on the assaymethodology and the timepoint of measurement. Sensitization with formation of ADAsis associated with an increased risk of infusion reactions, accelerated drug clearance, and a loss of response (LOR) to drug. Recently, a greater understanding of the pharmacokinetics of therapeutic antibodies has led to the development of new strategies to reduce immunogenicity and more efficient use of these drugs. These preventive strategies include regular scheduled dosing with maintenance of stable therapeutic trough drug concentrations, and co-administration of an immunosuppressive. Sub-therapeutic drug concentrations with escalation, whereas the presence of high concentrations of ADAs requires a switch to another therapeutic agent.},
  author       = {Hindryckx, Pieter and Novak, Gregor and Vande Casteele, Niels and Khanna, Reena and Laukens, Debby and Vipul, Jairath and Feagan, Brian G},
  issn         = {0012-6667},
  journal      = {DRUGS},
  keywords     = {PLACEBO-CONTROLLED TRIAL,INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY,CROHNS-DISEASE,MAINTENANCE THERAPY,RHEUMATOID-ARTHRITIS,CERTOLIZUMAB PEGOL,DOUBLE-BLIND,INFLIXIMAB ANTIBODIES,ULCERATIVE-COLITIS,EPISODIC TREATMENT},
  language     = {eng},
  number       = {4},
  pages        = {363--377},
  title        = {Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease : a practical overview},
  url          = {http://dx.doi.org/10.1007/s40265-017-0693-5},
  volume       = {77},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: